Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Topical Drug Delivery Market to Reach $362.3 Billion by 2031, Driven by Rising Prevalence of Skin Disorders and Innovation in Non-Invasive Delivery Technologies

globenewswire.com
ABBV AbbVie Inc. is mentioned as a diversified multinational pharmaceutical company operating in the global topical drug delivery market, which is projected to grow significantly. The article does not provide specific sentiment towards AbbVie. ALM Almirall is mentioned as a company involved in AI-driven drug discovery collaborations and as part of the competitive landscape in the topical drug delivery market. The article does not provide specific sentiment. BHC Bausch Health Companies Inc. is identified as a diversified multinational pharmaceutical and consumer health company within the topical drug delivery market. The article does not convey specific sentiment. GILD While not explicitly mentioned, Gilead Sciences is a major player in the pharmaceutical industry and could be involved in topical drug delivery. However, based solely on the article's text, no specific mention or sentiment can be extracted. GSK GSK plc is mentioned as a diversified multinational pharmaceutical and consumer health company within the competitive landscape of the topical drug delivery market. No specific sentiment is expressed. SNY Sanofi is mentioned as a diversified multinational pharmaceutical company in the competitive landscape of the topical drug delivery market. The article does not convey specific sentiment. SOLV Solventum is listed as a diversified multinational pharmaceutical and consumer health company in the competitive landscape of the topical drug delivery market. No specific sentiment is expressed. TEVA Teva Pharmaceutical Industries Ltd. is identified as a diversified multinational pharmaceutical company within the competitive landscape of the topical drug delivery market. The article does not convey specific sentiment.

Global Topical Drug Delivery Market to Reach $362.3 Billion by 2031, Driven by Rising Prevalence of Skin Disorders and Innovation in Non-Invasive Delivery Technologies Boston, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The global topical drug delivery market is projected to grow from $222.9 billion in 2025 to $362.3 billion by 2031, at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2031, according to the BCC Research report Global Topical Drug Delivery Market. This expansion reflects mounting disease burden, accelerating pharmaceutical R&D investment, and a pipeline of next-generation delivery technologies reshaping dermatological therapeutics.

Key Findings

• Market Scale and Growth Trajectory: The global topical drug delivery market is valued at $222.9 billion in 2025 and is forecast to reach $362.3 billion by 2031, at a CAGR of 8.7% (2026–2031), underpinned by surging demand for non-invasive treatment modalities and expanding regulatory approvals for novel topical formulations.

• Regional Leadership: North America holds the largest regional share at 46.5%, supported by strong OTC and prescription topical medicine adoption, robust dermatological infrastructure, and the influence of organizations such as the American Academy of Dermatology. The region accounts for 54.8% of total global pharmaceutical sales, reinforcing its commercial dominance.

• Disease Burden as a Structural Demand Driver: The scale of unmet dermatological need is substantial. Atopic dermatitis affects approximately 204 million people globally, psoriasis impacts more than 60 million, and fungal skin diseases accounted for roughly 1.73 billion cases worldwide in 2021. This persistent and growing disease burden is translating directly into sustained demand for effective topical therapies.

• Pharmaceutical R&D Investment Accelerating Innovation: Global pharmaceutical R&D spending reached nearly $288 billion in 2024, fuelling a robust pipeline of topical drug candidates. Recent regulatory milestones — including FDA approval of Zoryve topical foam for psoriasis in 2023 and the expanded Opzelura indication in 2024 — demonstrate the pipeline's commercial maturity and signal continued approvals ahead.

• Emerging Technologies Enhancing Efficacy and Adherence: The technology landscape is advancing rapidly. Microneedle-based drug delivery systems, nanoparticle formulations including lipid-polymer hybrid carriers, smart transdermal patches with stimuli-responsive release, 3D-printed topical formulations, and RNA-based topical treatments such as CosmeRNA for hair loss are collectively improving drug penetration, patient adherence, and therapeutic precision. AI-driven drug discovery collaborations — including the partnership between Almirall and Absci — and microneedle patch platforms under development by Daewoong Pharmaceutical further illustrate the sector's innovation velocity.

• Competitive Landscape: The market features a diversified group of multinational pharmaceutical and consumer health companies, including AbbVie Inc., Almirall, Bayer AG, Bausch Health Companies Inc., Galderma, Glenmark Pharmaceuticals Ltd., GSK plc, Haleon plc, Hisamitsu Pharmaceutical Co. Inc., Kenvue, LEO Pharma A/S, Sanofi, Solventum, and Teva Pharmaceutical Industries Ltd.

Market Drivers

The topical drug delivery market is being shaped by two converging structural forces: an escalating global burden of chronic skin disease and a meaningful shift in patient and prescriber preference toward non-invasive, painless drug delivery alternatives. With hundreds of millions of patients affected by atopic dermatitis, psoriasis, and fungal skin conditions, the demand for effective, well-tolerated topical therapies is both large and durable. Simultaneously, growing aversion to injectable therapies — particularly among patients managing chronic conditions requiring long-term treatment — is driving formulators and developers toward transdermal and topical platforms that can achieve comparable systemic or local efficacy without needles.

These demand-side tailwinds are reinforced by supply-side momentum. Rising R&D expenditure is accelerating the translation of advanced delivery technologies — including nanocarriers, nanoemulsions, permeation enhancers, and AI-assisted drug discovery — into commercially viable products. Regulatory progress, while complex, is validating new entrants into the market, with recent FDA approvals demonstrating that the regulatory pathway for differentiated topical formulations is navigable for well-resourced sponsors.

Investment Considerations

Investors should view the global topical drug delivery market as a high-growth segment with durable demand fundamentals and a technology-driven expansion runway. The 8.7% CAGR through 2031 reflects not merely volume growth but a structural shift toward higher-value, technology-enhanced formulations that command premium pricing and stronger intellectual property protection. Companies best positioned to capture outsized returns include those with diversified pipelines spanning both prescription dermatology and OTC categories, as well as those investing in platform technologies such as microneedle systems, nanocarrier formulations, and AI-enabled drug discovery. Key risks include regulatory complexity surrounding nanomaterial-based and combination drug-device products — with 50% of stakeholders citing unclear guidance for nanomaterials — alongside drug development costs estimated at approximately $3.6 billion per new drug over timelines of 12 to 13 years. European market participants face additional approval friction for follow-on topical products under Article 10(3) of Directive 2001/83/EC. Regional disparities in access and commercialization remain a constraint on global revenue expansion.

About the Report

The Global Topical Drug Delivery Market provides comprehensive market sizing, segmentation, competitive intelligence, and forecasts through 2031, covering the full spectrum of topical and transdermal drug delivery technologies, product types, and geographic markets.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.